(Q44852462)

6 December 2017

title

Measuring treatment preferences and willingness to pay for docetaxel in advanced ovarian cancer (English)

1 reference

6 December 2017

1 reference

1 reference

1

George Dranitsaris

1 reference

6 December 2017

Julia Elia-Pacitti

2

1 reference

6 December 2017

Wayne Cottrell

series ordinal

3

1 reference

6 December 2017

publication date

1 January 2004

1 reference

6 December 2017

1 reference

6 December 2017

volume

22

1 reference

6 December 2017

issue

6

1 reference

6 December 2017

page(s)

375-387

1 reference

What are cancer patients willing to pay for prophylactic epoetin alfa? A cost-benefit analysis

6 December 2017

cites work

1 reference

12 December 2020

Willingness-to-pay as a measure of benefits. Relevant questions in the context of public decisionmaking about health care programs

1 reference

12 December 2020

Treatment of advanced ovarian cancer

1 reference

12 December 2020

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

1 reference

12 December 2020

When do the "dollars" make sense? Toward a conceptual framework for contingent valuation studies in health care

1 reference

12 December 2020

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

1 reference

12 December 2020

Assessment of the Relationship Between Measures of Disease Severity, Quality of Life, and Willingness to Pay in Asthma

1 reference

12 December 2020

An empirical note on willingness to pay and starting-point bias.

1 reference

12 December 2020

A multinational study to measure the value that patients with cancer place on improved emesis control following cisplatin chemotherapy.

1 reference

12 December 2020

Cost-utility analysis of chemotherapy using paclitaxel, docetaxel, or vinorelbine for patients with anthracycline-resistant breast cancer

1 reference

12 December 2020

Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer.

1 reference

12 December 2020

Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group

1 reference

12 December 2020

10.2165/00019053-200422060-00004

Identifiers

DOI

1 reference

Dimensions Publication ID

6 December 2017

1023144104

0 references

1 reference